By this means, recently published data showed that downregulation of key proteins involved in T cells terminal differentiation and exhaustion such as NR4A, TOX/TOX2, TET2, Regnase1, or PTPN22 [96,97,98,99,100] increased T cell-based treatment half-life and improve anti-tumor performance. This evidence concerns the gene PTPN22 and neoplasm.